PDCD1 and neoplasm: Moreover, RT (3 × 8 Gy) plus anti-PD-1 antibody combined with an antibody targeting T-cell immunoreceptor with Ig and ITIM domains (TIGIT) led to a significant anti-tumor effect in CT26 and B16-F10 models, which was less effective with RT and either antibody alone [11].